-
EP3850371
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3850371
| EP3850371 - METHOD FOR DIAGNOSING A LIVER DISEASE [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 24.02.2023 Database last updated on 14.11.2024 | |
| Former | Examination is in progress Status updated on 17.06.2022 | ||
| Former | Request for examination was made Status updated on 18.06.2021 | ||
| Former | The international publication has been made Status updated on 21.03.2020 | ||
| Former | unknown Status updated on 30.09.2019 | Most recent event Tooltip | 24.02.2023 | Application deemed to be withdrawn | published on 29.03.2023 [2023/13] | Applicant(s) | For all designated states Fianostics GmbH Viktor-Kaplan-Straße 2 2700 Wiener Neustadt / AT | [2021/29] | Inventor(s) | 01 /
HAWA, Gerhard Untere Kaistraße 24/6/8 1100 Wien / AT | 02 /
MISSBICHLER, Albert Kummergasse 8/1/18 1210 Wien / AT | [2021/29] | Representative(s) | Pföstl, Andreas Schwarz & Partner Patentanwälte Wipplingerstraße 30 1010 Wien / AT | [2021/29] | Application number, filing date | 19772645.8 | 11.09.2019 | [2021/29] | WO2019AT60300 | Priority number, date | AT20180050781 | 12.09.2018 Original published format: AT 507812018 | [2021/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020051617 | Date: | 19.03.2020 | Language: | EN | [2020/12] | Type: | A1 Application with search report | No.: | EP3850371 | Date: | 21.07.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.03.2020 takes the place of the publication of the European patent application. | [2021/29] | Search report(s) | International search report - published on: | EP | 19.03.2020 | Classification | IPC: | G01N33/68 | [2021/29] | CPC: |
G01N33/6893 (EP,US);
C12Q1/00 (AT);
B82Y30/00 (AT);
G01N21/64 (AT);
G01N33/543 (AT,US);
G01N2333/51 (EP);
G01N2800/085 (EP,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/29] | Title | German: | VERFAHREN ZUR DIAGNOSE VON LEBERERKRANKUNGEN | [2021/29] | English: | METHOD FOR DIAGNOSING A LIVER DISEASE | [2021/29] | French: | PROCÉDÉ DE DIAGNOSTIC D'UNE MALADIE HÉPATIQUE | [2021/29] | Entry into regional phase | 09.04.2021 | National basic fee paid | 09.04.2021 | Designation fee(s) paid | 09.04.2021 | Examination fee paid | Examination procedure | 08.07.2020 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 09.04.2021 | Examination requested [2021/29] | 09.04.2021 | Date on which the examining division has become responsible | 05.10.2021 | Amendment by applicant (claims and/or description) | 21.06.2022 | Despatch of a communication from the examining division (Time limit: M04) | 03.11.2022 | Application deemed to be withdrawn, date of legal effect [2023/13] | 23.11.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2023/13] | Fees paid | Renewal fee | 30.09.2021 | Renewal fee patent year 03 | 30.09.2022 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y] - NAGA CHALASANI ET AL, "The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases", HEPATOLOGY, (20170717), vol. 67, no. 1, doi:10.1002/hep.29367, ISSN 0270-9139, pages 328 - 357, XP055632257 [Y] 1-11 * (p 330, col 2, 2nd para from the bottom; p 335, col 1, last para ff; title;; table 2 * DOI: http://dx.doi.org/10.1002/hep.29367 | [Y] - AHILAN ARULANANDAN ET AL, "Noninvasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?", CURRENT HEPATOLOGY REPORTS, (20150422), vol. 14, no. 2, doi:10.1007/s11901-015-0263-9, pages 109 - 118, XP055585976 [Y] 1-11 * abstr; p 2, para 3 ff; tables 1a, 1b and 2; p 8, past para * DOI: http://dx.doi.org/10.1007/s11901-015-0263-9 | [Y] - BEI LI ET AL, "Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis", CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, (20180702), vol. 2018, doi:10.1155/2018/2784537, ISSN 2291-2789, pages 1 - 8, XP055640229 [Y] 1-11 * p 3, col 1, para 3 ff; abstr * DOI: http://dx.doi.org/10.1155/2018/2784537 | [Y] - BLANCA HERRERA ET AL, "BMP Signalling at the Crossroad of Liver Fibrosis and Regeneration", INT. J. MOL. SCI., (20171223), vol. 19, no. 1, doi:10.3390/ijms19010039, ISSN 1661-6596, page 39, XP055640010 [Y] 1-16 * abstract * DOI: http://dx.doi.org/10.3390/ijms19010039 | [Y] - N. DO ET AL, "BMP4 is a novel paracrine inhibitor of liver regeneration", AMERICAN JOURNAL OF PHYSIOLOGY: GASTROINTESTINAL AND LIVER PHYSIOLOGY, (20120927), vol. 303, no. 11, doi:10.1152/ajpgi.00105.2012, ISSN 0193-1857, pages G1220 - G1227, XP055188353 [Y] 1-16 * abstract * DOI: http://dx.doi.org/10.1152/ajpgi.00105.2012 | [Y] - HAWA G ET AL, "Single step, direct fluorescence immunoassays based on metal enhanced fluorescence (MEF-FIA) applicable as micro plate-, array-, multiplexing- or point of care-format", ANALYTICAL BIOCHEMISTRY, ELSEVIER, AMSTERDAM, NL, (20180305), vol. 549, doi:10.1016/J.AB.2018.03.002, ISSN 0003-2697, pages 39 - 44, XP085392615 [Y] 1-16 * (p 41, col 1, para 1-2)(p 42, col 2, para 1 ff)(table 1; p 43, col 2, para 1)(p 43, col 2, last para)(p 42, col 2, para 1-2; fig 7) * DOI: http://dx.doi.org/10.1016/j.ab.2018.03.002 | [XP] - G Hawa ET AL, "Background", Fianostics Fluorescence Immunoassays, (20190801), pages 1 - 1, URL: https://eaglebio.com/wp-content/uploads/2019/08/190728_AACC-2019.pdf, (20191107), XP055640007 [XP] 1-16 * the whole document * | Examination | WO2017046320 | by applicant | WO2017046320 | - AMARAPURKAR et al., Ann Hepatol, (20070000), vol. 6, pages 161 - 163 | - HIGUCHIGORES, Curr Mol Med, (20030000), vol. 3, pages 483 - 490 | - POLYZOS S et al., Ann Hepatol, (20130000), vol. 12, no. 5, pages 749 - 757 | - POLYZOS SA et al., Diabetes Obes Metab., (20170000), vol. 19, no. 12, pages 1805 - 1809 | - POLYZOS SA et al., Diabetes Obes Metab, (20170000), vol. 19, no. 12, pages 1805 - 1809 | - HAWA G et al., Anal Biochem., (20180515), vol. 549, pages 39 - 44 | - KLEINER DE et al., Hepatology, (20050000), vol. 41, no. 6, pages 1313 - 1321 |